ERBB2 and neoplasm: In contrast to our findings that celecoxib did not reduce tumor multiplicity of hormonally nonresponsive mammary carcinomas, tumor multiplicity was reduced by 41% in mouse mammary tumor virus-neu transgenic mice at a dose of 900 ppm [9].